- Home
- BYRN vs LUCD Comparison
BYRN vs LUCD Comparison
Compare BYRN & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYRN | LUCD |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.6M | 190.8M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BYRN | LUCD |
|---|---|---|
| Price | $6.29 | $1.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $23.17 | $4.13 |
| AVG Volume (30 Days) | ★ 650.7K | 639.7K |
| Earning Date | 04-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $16,566,295.00 | $4,346,000.00 |
| Revenue This Year | $17.30 | $126.14 |
| Revenue Next Year | $16.48 | $138.77 |
| P/E Ratio | $223.00 | ★ N/A |
| Revenue Growth | ★ 1692.08 | 79.00 |
| 52 Week Low | $5.56 | $0.95 |
| 52 Week High | $33.56 | $1.70 |
Technical Indicators
Market Signals| Indicator | BYRN | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 50.44 |
| Support Level | N/A | $1.01 |
| Resistance Level | $10.00 | $1.52 |
| Average True Range (ATR) | 0.70 | 0.08 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 18.69 | 45.15 |
Price Performance
Historical ComparisonAbout BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.